Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
BMC Infect Dis ; 14: 636, 2014 Nov 30.
Article in English | MEDLINE | ID: mdl-25433390

ABSTRACT

BACKGROUND: While cultivation of pathogens represents a foundational diagnostic approach in the study of infectious diseases, its value for the confirmation of clinical diagnosis of Buruli ulcer is limited by the fact that colonies of Mycobacterium ulcerans appear only after about eight weeks of incubation at 30°C. However, for molecular epidemiological and drug sensitivity studies, primary isolation of M. ulcerans remains an essential tool. Since for most of the remote Buruli ulcer endemic regions of Africa cultivation laboratories are not easily accessible, samples from lesions often have to be stored for extended periods of time prior to processing. The objective of the current study therefore was to determine which transport medium, decontamination method or other factors decrease the contamination rate and increase the chance of primary isolation of M. ulcerans bacilli after long turnover time. METHODS: Swab and fine needle aspirate (FNA) samples for the primary cultivation were collected from clinically confirmed Buruli ulcer patients in the Mapé Basin of Cameroon. The samples were either stored in the semi-solid transport media 7H9 or Amies or dry for extended period of time prior to processing. In the laboratory, four decontamination methods and two inoculation media were evaluated and statistical methods applied to identify factors that decrease culture contamination and factors that increase the probability of M. ulcerans recovery. RESULTS: The analysis showed: i) that the use of moist transport media significantly increased the recovery rate of M. ulcerans compared to samples kept dry; ii) that the choice of the decontamination method had no significant effect on the chance of M. ulcerans isolation; and iii) that Löwenstein-Jensen supplemented with antibiotics as inoculation medium yielded the best results. We further found that, ten extra days between sampling and inoculation lead to a relative decrease in the isolation rate of M. ulcerans by nearly 20%. Finally, collection and processing of multiple samples per patient was found to significantly increase the M. ulcerans isolation rate. CONCLUSIONS: Based on our analysis we suggest a procedure suitable for the primary isolation of M. ulcerans strains from patients following long delay between sample collection and processing to establish a M. ulcerans strain collection for research purposes.


Subject(s)
Buruli Ulcer/microbiology , Mycobacterium ulcerans/growth & development , Mycobacterium ulcerans/isolation & purification , Specimen Handling/methods , Cameroon , Culture Media , Humans , Mycobacterium ulcerans/cytology , Time Factors
2.
PLoS Negl Trop Dis ; 4(7): e736, 2010 Jul 06.
Article in English | MEDLINE | ID: mdl-20625556

ABSTRACT

BACKGROUND: The World Health Organization (WHO) advises treatment of Mycobacterium ulcerans disease, also called "Buruli ulcer" (BU), with a combination of the antibiotics rifampicin and streptomycin (R+S), whether followed by surgery or not. In endemic areas, a clinical case definition is recommended. We evaluated the effectiveness of this strategy in a series of patients with large ulcers of > or =10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC). METHODS: A cohort of 92 patients with large ulcerated lesions suspected to be BU was enrolled between October 2006 and September 2007 and treated according to WHO recommendations. The following microbiologic data were obtained: Ziehl-Neelsen (ZN) stained smear, culture and PCR. Histopathology was performed on a sub-sample. Directly observed treatment with R+S was administered daily for 12 weeks and surgery was performed after 4 weeks. Patients were followed up for two years after treatment. FINDINGS: Out of 92 treated patients, 61 tested positive for M. ulcerans by PCR. PCR negative patients had better clinical improvement than PCR positive patients after 4 weeks of antibiotics (54.8% versus 14.8%). For PCR positive patients, the outcome after 4 weeks of antibiotic treatment was related to the ZN positivity at the start. Deterioration of the ulcers was observed in 87.8% (36/41) of the ZN positive and in 12.2% (5/41) of the ZN negative patients. Deterioration due to paradoxical reaction seemed unlikely. After surgery and an additional 8 weeks of antibiotics, 98.4% of PCR positive patients and 83.3% of PCR negative patients were considered cured. The overall recurrence rate was very low (1.1%). INTERPRETATION: Positive predictive value of the WHO clinical case definition was low. Low relapse rate confirms the efficacy of antibiotics. However, the need for and the best time for surgery for large Buruli ulcers requires clarification. We recommend confirmation by ZN stain at the rural health centers, since surgical intervention without delay may be necessary on the ZN positive cases to avoid progression of the disease. PCR negative patients were most likely not BU cases. Correct diagnosis and specific management of these non-BU ulcers cases are urgently needed.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Buruli Ulcer/diagnosis , Buruli Ulcer/drug therapy , Mycobacterium ulcerans/isolation & purification , Rifampin/therapeutic use , Streptomycin/therapeutic use , Adolescent , Adult , Aged , Bacteriological Techniques , Buruli Ulcer/microbiology , Child , Child, Preschool , Cohort Studies , Democratic Republic of the Congo , Female , Histocytochemistry , Humans , Male , Middle Aged , Mycobacterium ulcerans/cytology , Mycobacterium ulcerans/genetics , Mycobacterium ulcerans/growth & development , Prospective Studies , Treatment Outcome , Young Adult
3.
Future Microbiol ; 5(3): 363-70, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20210548

ABSTRACT

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, has become the third most common mycobacterial disease worldwide. Antimycobacterial therapy is considered the treatment of choice. With the introduction of antimycobacterial treatment, laboratory confirmation of clinically suspected cases became crucial for the clinical management of BUD. Currently available diagnostic laboratory tests include microscopy, culture, histopathology and IS2404 PCR. Several IS2404 PCR assays were applied for case confirmation in endemic countries, and IS2404 PCR is considered the most sensitive method for the laboratory confirmation of BUD. Due to the extended presence of mycobacterial DNA under antimycobacterial treatment, however, PCR is not suitable for monitoring of treatment success. Currently, cultures are considered the only valid confirmatory test for the detection of viable bacilli.


Subject(s)
Bacteriological Techniques/methods , Buruli Ulcer/diagnosis , Histocytochemistry , Microscopy , Mycobacterium ulcerans/isolation & purification , Polymerase Chain Reaction , Buruli Ulcer/microbiology , Buruli Ulcer/pathology , DNA Transposable Elements , DNA, Bacterial/genetics , Drug Monitoring , Humans , Mycobacterium ulcerans/cytology , Mycobacterium ulcerans/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...